BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

Published on June 16, 2023

BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development

Continue reading on website
Other news

Swiss company Lonza acquires Synaffix to boost ADC offering

June 16, 2023
Switzerland-based company Lonza has boosted its antibody-drug conjugates (ADCs) offering with the acquisition of Dutch biotechnology company Synaffix for a total consideration of $172m (€160m).The deal includes $107.17m (€100m) of initial financial consideration in cash and an additional $64.3m (€60m) in performance-based consideration.Synaffix is focused on the commercialisation of its clinical-s

Eikon Therapeutics bag $106m to fund eager acquisitions

June 16, 2023
San Francisco-based biotech Eikon Therapeutics has made waves in the bay after managing to raise $106m in its Series C funding round.This latest cash injection will be used to fund and support a range of acquisitions intended to diversify their development pipeline, which were announced alongside the fundraise, as per a 1 June announcement.The company acquired the global rights to develop and comm